Juno Therapeutics (JUNO) Posts Q4 Loss of $1.61/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics Reports Fourth Quarter and 2014 Financial Results
March 18, 2015 4:02 PM EDTConference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time
Positive momentum and progress on clinical trials continues Strong year-end cash position of $474.1 million 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and ongoing litigationSEATTLE, March 18, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial... More
Juno Therapeutics Reports Fourth Quarter and 2014 Financial Results
March 18, 2015 4:02 PM EDTConference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time
Positive momentum and progress on clinical trials continues Strong year-end cash position of $474.1 million 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and ongoing litigationSEATTLE, March 18, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial... More
